Related Experiment Video
Updated: Aug 29, 2025
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Small Synthetic Hyaluronan Disaccharide BIS014 Mitigates Neuropathic Pain in Mice
Juan-Fernando Padín1, Marcos Maroto2, José Manuel Entrena3
1Instituto-Fundación Teófilo Hernando, C/ Faraday 7, Parque Científico del Campus de Cantoblanco, Universidad Autónoma de Madrid, Madrid, Spain; Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Avda. Arzobispo Morcillo 4, Madrid, Spain; Departamento de Ciencias Médicas (Farmacología), Facultad de Medicina, Universidad de Castilla-La Mancha, Ciudad Real, Spain.
A novel sulfated disaccharide, BIS014, effectively reduced neuropathic pain in mice across various models. Unlike gabapentin, BIS014 demonstrated analgesic effects without causing sedation or motor impairment, offering a promising new treatment option.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- Neuropathic pain (NP) presents a significant unmet medical need due to limited effective treatments.
- Current therapies often cause undesirable side effects, necessitating the development of novel analgesics.
Purpose of the Study:
- To investigate the analgesic potential of a new sulfated disaccharide compound, BIS014, for treating neuropathic pain.
- To evaluate the safety and efficacy profile of BIS014 compared to gabapentin.
Main Methods:
- BIS014 was administered orally to mice in various NP models, including spared nerve injury, chemotherapy-induced NP, and diabetic neuropathy.
- Behavioral tests assessed nociception, mechanical hypersensitivity, exploratory activity, and motor coordination.
- In silico (docking, molecular dynamics) and in vitro (calcium imaging, electrophysiology) studies investigated BIS014's interaction with TRPV1 receptors.
Main Results:
- Oral BIS014 significantly ameliorated pain behaviors in multiple NP models.
- BIS014 demonstrated efficacy at doses that did not impair motor coordination or exploratory activity.
- In silico and in vitro studies indicated BIS014 interacts with TRPV1 receptors as a partial agonist, modulating neuronal excitability.
Conclusions:
- BIS014 exhibits significant analgesic effects in diverse models of neuropathic pain.
- BIS014 represents a potential non-sedative, orally available therapeutic agent for neuropathic pain management.
- The compound's mechanism involves interaction with TRPV1, offering a novel approach to pain treatment.
